TMDI News and Press, Titan Medical Inc. From 05/18/22

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will present an overview of its Enos™ robotic single access surgical system at the H.C. Wainwright Global Investme...

Titan Medical Inc. (TMDI) Q1 2022 Results Conference Call May 12, 2022 08:30 AM ET Company Participants Kristen Galfetti - Vice President of Investor Relations Paul Cataford - Interim President & CEO Stephen Lemieux - Chief Financial Officer Conference Call Participants Suraj Kalia - Oppe...

Manufacturing Team and Capabilities Continue to Expand Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced...

Titan Medical (NASDAQ:TMDI) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close. The consensus EPS Estimate is -$0.10 (+33.3% Y/Y) and the consensus Revenue Estimate is nil. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. ...

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that its 2022 Annual and Special Meeting (“the Meeting ...

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced receipt of a $2.6 million purchase order from Medtronic plc (NYSE:...

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its first quarter 2022 financial results prior to market opening on Thursday, May 12, 2022. In addition, man...

Titan Medical's (TMDI -6.0%) stock fell following its FY21 results. For full year 2021, research and development expenses (R&D) rose to $37.9M, compared to $7.9M in 2020. The company said R&D expenses were related to the development of its robotic single access surgical syst...

Titan Medical Inc. (TMDI) Q4 2021 Earnings Conference Call March 24, 2022 8:30 AM ET Company Participants Kristen Galfetti - Vice President of Investor Relations Paul Cataford - Interim President and CEO Stephen Lemieux - Chief Financial Officer Conference Call Participants Suraj Kalia - Oppe...

Completed Final Milestone with Medtronic Selected Benchmark to Manufacture Enos System Expanded Patent Portfolio to More Than 200 Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative ...